Impressive or Terrifying?; Locals react to new technology, turning AI photos into videosLocal FedEx employees at risk of losing their jobs
FILE – In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. On Thursday, Oct. 22, 2020, the U.S. Food and Drug Administration has approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given through an IV for patients needing hospitalization. The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days on average in a large study led by the U.S. National Institutes of Health. (Gilead Sciences via AP) The U.S. Food and Drug Administration has approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given through an IV for patients needing hospitalization. The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days – from 15 days to 10 on average – in a large study led by the U.S. National Institutes of Health. It had been authorized for use on an emergency basis since spring, and now has become the first drug to win full U.S. approval for treating COVID-19. Gilead says Veklury is approved for people at least 12 years old and weighing at least 88 pounds (40 kilograms) who need hospitalization for their coronavirus infection. It works by inhibiting a substance the virus uses to make copies of itself.